As part of its collaboration agreement with the French firm, Cellectis is eligible for an undisclosed payment. Signed in February 2014, the collaboration is focused on research, development
Each year, manufacturers of influenza vaccine must receive approval from the FDA for changes they make to their vaccines so that the vaccines protect against the new strains
Arrowhead’s ARC-AAT is being investigated for the treatment of liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD). The Phase I trial is currently enrolling
As part of the collaboration, both the parties will identify and co-fund translational research projects with leading academic medical centers within the CTI network. JMF noted that the
Non-24 is a chronic, circadian rhythm disorder which results from the misalignment of the endogenous master body clock to the 24-hour day, disrupting the sleep-wake cycle. Hetlioz is
DX-2930 is currently being developed by the company as a subcutaneous injection for prevention of HAE attacks. The company noted that uncontrolled pKal activity leads to excessive generation
As part of this deal, the university is looking forward to advancing new formulations of CBD to meet serious medical conditions where non-psychotropic cannabinoids can play a significant
Around 60 healthy volunteers will be enrolled in the randomized, double-blinded, placebo-controlled Phase I trial, which is currently underway in Belgium. The company said that potential indications for
Under the deal, Incyte will provide financial support for Vanderbilt’s grant-based research program, which has an initial collaboration period of three years, with the option to extend. The
The deal is subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR). Allergan will buy these rights for an
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.